NDAINTRAVENOUSSOLUTIONPriority Review
Approved
Jan 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 6d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MIVACRON (mivacurium chloride) is a short-acting depolarizing neuromuscular blocking agent administered intravenously for use during anesthesia. It works by binding to acetylcholine receptors at the neuromuscular junction to produce rapid muscle relaxation. The drug is primarily used to facilitate intubation and provide skeletal muscle relaxation during surgical procedures.
LOE Approaching
With LOE approaching and moderate competitive pressure (30), the brand team is likely small and focused on defending market share rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on MIVACRON offers limited career growth due to its LOE-approaching status and minimal linked job openings. Roles on this product are primarily defensive and focused on managing decline rather than driving innovation or expansion.
Brand ManagerField Sales Representative
Worked on MIVACRON at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.